Results 71 to 80 of about 38,538 (308)

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

iScience
Summary: A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, Yuko Okemoto-Nakamura, Yoshimi Shimizu, Motohiko Ogawa, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Mika K. Kaneko, Masayoshi Fukasawa, Yukinari Kato, Kohji Noguchi   +12 more
doaj   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source

Expression of an anti-CD33 single-chain antibody by Pichia pastoris [PDF]

, 2005
CD33 is a cell surface glycoprotein expressed on cells of myelomonocytic lineage, leukaemic cells, but not haematopoietic stem cells. By virtue of its expression pattern, CD33 has become a popular target for new immunotherapeutic approaches to treat ...
Emberson, Louise M., Trivett, Amanda J., Blower, Philip J., Nicholls, Peter J.   +3 more
core   +1 more source

Chemical generation of bispecific antibodies [PDF]

Proceedings of the National Academy of Sciences, 2010
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Venkata R, Doppalapudi, Jie, Huang, Dingguo, Liu, Ping, Jin, Bin, Liu, Lingna, Li, Joel, Desharnais, Crystal, Hagen, Nancy J, Levin, Michael J, Shields, Michelle, Parish, Robert E, Murphy, Joselyn, Del Rosario, Bryan D, Oates, Jing-Yu, Lai, Marla J, Matin, Zemeda, Ainekulu, Abhijit, Bhat, Curt W, Bradshaw, Gary, Woodnutt, Richard A, Lerner, Rodney W, Lappe   +21 more
openaire   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions

Frontiers in Immunology
Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies.
Zhijuan Ai, Zhijuan Ai, Bing Wang, Yunlong Song, Panpan Cheng, Xinlin Liu, Xinlin Liu, Peng Sun   +7 more
doaj   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

mAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero, Katharina B. Kroell, Lukas J. Grunewald, Anna-Lena M. Fischer, Jakob R. Riccabona, Klaus R. Liedl   +5 more
doaj   +1 more source

Bispecific antibodies: design, therapy, perspectives

Drug Design, Development and Therapy, 2018
Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers ...
Sergey Sedykh, Victor Prinz, Valentina Buneva, Georgy Nevinsky   +3 more
openaire   +4 more sources

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source